InsiderPulse
Dashboard

VRTX

Vertex Pharmaceuticals

Health CareS&P 500NASDAQ 100

Vertex Pharmaceuticals insider trading

Vertex Pharmaceuticals files with the SEC as a Pharmaceutical Preparations company headquartered in Boston, MA. Every time one of its executives or directors buys or sells the stock, the filing appears here the moment it reaches the SEC — with grants and option exercises set apart from the trades that cost the insider their own money.

From SEC filings

Recent VRTX insider transactions

6 insiders traded VRTX on the open market between May 01, 2026 and Jul 02, 2026 — 14 sales worth $11M, of which every one was pre-scheduled under a 10b5-1 plan.

Bought
—
Sold
$11M

14 of 14 on a 10b5-1 plan

Net
−$11M
Insiders
6

Open-market purchases (code P) and sales (code S) from Vertex Pharmaceuticals's own SEC Form 4 filings. Grants and option exercises are excluded — they are compensation, not decisions. Share counts are derived from the reported value and price. Verify any figure against the original filing before acting on it; this is monitoring, not advice.

Filing history last read from EDGAR on Sep 20, 2026. The live dashboard shows new filings the moment they clear.

Every VRTX Form 4 on SEC.gov

SEC Form 4 data, Q3 2024 to Q2 2026

VRTX insider trading by quarter

Between Jul 01, 2024 and Jun 30, 2026, 15 insiders traded VRTX on the open market: 4 purchases worth $5.8M and 128 sales worth $209.5M, every sale pre-scheduled under a 10b5-1 plan. In the last four quarters alone: 4 purchases ($5.8M) and 92 sales ($156.5M), by 14 insiders.

QuarterBoughtSold
Q2 2026—−$9.4M12 sales · all on a plan
Q1 2026—−$76.1M56 sales · all on a plan
Q4 2025—−$70.9M23 sales · all on a plan
Q3 2025+$5.8M4 buys−$102.9K1 sale · all on a plan
Q2 2025—−$224.4K2 sales · all on a plan
Q1 2025—−$18.9M21 sales · all on a plan
Q4 2024—−$9.9M4 sales · all on a plan
Q3 2024—−$24M9 sales · all on a plan
Largest purchase
+$2.2M of VRTX by Kewalramani Reshma (CEO & President · Director) on Aug 06, 2025.
Largest sale
−$14.2M of VRTX by Leiden Jeffrey M (Executive Chairman · Director) on Nov 14, 2025, under a 10b5-1 plan.

Open-market transactions through Jun 30, 2026most recent first

  • Liu Joy10b5-1

    EVP and Chief Legal Officer

    −$439.3K

    Apr 01, 2026

    978 sh · $449.17

  • Bozic Carmen10b5-1

    EVP and CMO

    −$1.1M

    Mar 27, 2026

    2,329 sh · $450.95

  • Bozic Carmen10b5-1

    EVP and CMO

    −$1.1M

    Mar 13, 2026

    2,329 sh · $481.79

  • McKechnie Duncan10b5-1

    EVP, Chief Commercial Officer

    −$1.3M

    Mar 11, 2026

    2,633 sh · $498.42

  • McKechnie Duncan10b5-1

    EVP, Chief Commercial Officer

    −$1.2M

    Mar 04, 2026

    2,437 sh · $475.30

  • Liu Joy10b5-1

    EVP and Chief Legal Officer

    −$442.4K

    Mar 02, 2026

    892 sh · $495.96

  • Kewalramani Reshma10b5-1

    CEO & President · Director

    −$7.7M

    Feb 27, 2026

    15,580 sh · $495.38

  • Kewalramani Reshma10b5-1

    CEO & President · Director

    −$3M

    Feb 27, 2026

    5,995 sh · $496.16

  • Kewalramani Reshma10b5-1

    CEO & President · Director

    −$1.7M

    Feb 27, 2026

    3,498 sh · $494.33

  • Kewalramani Reshma10b5-1

    CEO & President · Director

    −$1.6M

    Feb 27, 2026

    3,278 sh · $488.27

  • Kewalramani Reshma10b5-1

    CEO & President · Director

    −$1.3M

    Feb 27, 2026

    2,725 sh · $490.54

  • Kewalramani Reshma10b5-1

    CEO & President · Director

    −$1.2M

    Feb 27, 2026

    2,520 sh · $493.29

  • Kewalramani Reshma10b5-1

    CEO & President · Director

    −$1.2M

    Feb 27, 2026

    2,510 sh · $487.13

  • Bozic Carmen10b5-1

    EVP and CMO

    −$1.1M

    Feb 27, 2026

    2,329 sh · $480.31

  • Kewalramani Reshma10b5-1

    CEO & President · Director

    −$857.2K

    Feb 27, 2026

    1,725 sh · $496.95

From SEC's quarterly Form 3, 4 and 5 data sets: code P purchases and code S sales of common stock, by the date the trade happened. Where a fund and the people who control it each report the same block, it is counted once. Trades made in the last days of Q2 2026 but filed after it closed arrive with SEC's next quarterly release.

Vertex Pharmaceuticals company record

SEC industry classification
Pharmaceutical Preparations
Headquarters
Boston, MA
Incorporated in
MA
Listed on
Nasdaq
SEC Central Index Key
0000875320

Sourced from this company's own SEC submissions record. The industry label is SEC's Standard Industrial Classification, which is more specific than the Health Care sector shown above.

After insiders bought VRTX

What the stock actually did in the 90 days following each open-market purchase

Don't check VRTX — let it ping you

Get told the moment an insider moves on VRTX

Pro watches Vertex Pharmaceuticals for you and sends a Telegram ping within moments of a Form 4 clearing EDGAR — a C-suite open-market buy, a cluster, a 10b5-1 regime break — long before it reaches the press. Add VRTX to a watchlist, see each mover's benchmark-measured track record and which legendary funds hold it, and read the full filing history instead of the last 72 hours.

Track VRTX on the live dashboardFilings on SEC.gov

The live dashboard is free to open. Alerts, watchlists, full filing history and each mover's benchmark-measured track record are Pro. Monitoring, not advice.

How to read VRTX insider activity

Open-market purchase (code P)
An insider spending their own money at market price. This is the only buy code that reliably carries signal — it is a decision, not compensation.
Grants and option exercises (codes A, M)
Scheduled compensation. Most "insider buying" headlines are really this, which is why InsiderPulse weights it at a fraction of a real purchase.
Cluster buy
Two or more different insiders buying on the open market in the same window. One executive buying can mean anything; three is much harder to explain away.

Other Health Care tickers

REGNISRGSYKBSXMDTCICVSELVHCAZTSMRNABIIB
This week on the tape: who actually chose to sellThe weekly split of scheduled 10b5-1 selling vs deliberate sales, with the deciders named.

Questions

Are VRTX insiders buying or selling?
Between May 01, 2026 and Jul 02, 2026, 6 Vertex Pharmaceuticals insiders made no open-market purchases and 14 sales worth $11M, a net sale of $11M. 14 of the sales were pre-scheduled under a Rule 10b5-1 plan.
How much VRTX stock have insiders bought and sold in the last two years?
Between Jul 01, 2024 and Jun 30, 2026, 15 Vertex Pharmaceuticals insiders made 4 open-market purchases worth $5.8M and 128 sales worth $209.5M. Every one of the sales was pre-scheduled under a Rule 10b5-1 plan. In the four quarters to Jun 30, 2026: 4 purchases ($5.8M) and 92 sales ($156.5M). The largest purchase was Kewalramani Reshma buying $2.2M on Aug 06, 2025. The largest sale was Leiden Jeffrey M selling $14.2M on Nov 14, 2025.
What was the largest recent VRTX insider trade?
Bozic Carmen (EVP and CMO) sold $3.1M of VRTX stock on May 12, 2026 at about $450.00 a share, under a pre-scheduled 10b5-1 plan.
When did an insider last buy VRTX shares?
No open-market purchase by a Vertex Pharmaceuticals insider appears in the filings from May 01, 2026 to Jul 02, 2026 — every recorded open-market transaction in that period was a sale. Before that, the most recent purchase in SEC's data was Kewalramani Reshma buying $2.2M on Aug 06, 2025.
Where does VRTX insider trading data come from?
From the Form 4 filings Vertex Pharmaceuticals's officers, directors and 10% owners must send the SEC within two business days of a trade. Each row on this page links to its original filing on SEC EDGAR. Share grants and option exercises are kept apart from open-market purchases and sales, because only the latter cost the insider their own money.

Get the free Insider Brief

Each weekday evening: the day's biggest open-market insider buys, cluster formations and 10b5-1 plan breaks — in plain English, with grants and routine vesting stripped out. Honest about what the data can and cannot say.

No account needed. One-click unsubscribe.